These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 27827871)

  • 21. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDSCs in cancer: Conceiving new prognostic and therapeutic targets.
    De Sanctis F; Solito S; Ugel S; Molon B; Bronte V; Marigo I
    Biochim Biophys Acta; 2016 Jan; 1865(1):35-48. PubMed ID: 26255541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
    Li BH; Garstka MA; Li ZF
    Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloid-derived suppressor cells (MDSC): an important partner in cellular/tissue senescence.
    Salminen A; Kauppinen A; Kaarniranta K
    Biogerontology; 2018 Oct; 19(5):325-339. PubMed ID: 29959657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
    Toor SM; Elkord E
    Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
    Wilkerson A; Kim J; Huang AY; Zhang M
    Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Characterization of Myeloid-Derived Suppressor Cells in Tumor Microenvironment.
    Li Y; He H; Jihu R; Zhou J; Zeng R; Yan H
    Front Cell Dev Biol; 2021; 9():698532. PubMed ID: 34527668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26.
    Chiu DK; Xu IM; Lai RK; Tse AP; Wei LL; Koh HY; Li LL; Lee D; Lo RC; Wong CM; Ng IO; Wong CC
    Hepatology; 2016 Sep; 64(3):797-813. PubMed ID: 27228567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
    Yamauchi Y; Safi S; Blattner C; Rathinasamy A; Umansky L; Juenger S; Warth A; Eichhorn M; Muley T; Herth FJF; Dienemann H; Platten M; Beckhove P; Utikal J; Hoffmann H; Umansky V
    Am J Respir Crit Care Med; 2018 Sep; 198(6):777-787. PubMed ID: 29617574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
    Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
    J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
    Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
    Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.
    Netherby CS; Messmer MN; Burkard-Mandel L; Colligan S; Miller A; Cortes Gomez E; Wang J; Nemeth MJ; Abrams SI
    J Immunol; 2017 May; 198(10):4129-4139. PubMed ID: 28356386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in understanding regulatory myeloid cells.
    Romano A; Vetro C; Adriani M
    Cancer Biol Ther; 2011 Jun; 11(11):923-6. PubMed ID: 21474999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond.
    Pastaki Khoshbin A; Eskian M; Keshavarz-Fathi M; Rezaei N
    Arch Immunol Ther Exp (Warsz); 2019 Apr; 67(2):89-102. PubMed ID: 30386868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid-derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy.
    Yin Z; Li C; Wang J; Xue L
    Int J Cancer; 2019 Mar; 144(5):933-946. PubMed ID: 29992569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coordinated Regulation of Myeloid-Derived Suppressor Cells by Cytokines and Chemokines.
    Li R; Mukherjee MB; Lin J
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
    Shariatpanahi SP; Shariatpanahi SP; Madjidzadeh K; Hassan M; Abedi-Valugerdi M
    J Theor Biol; 2018 Apr; 442():1-10. PubMed ID: 29337259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the origin of myeloid-derived suppressor cells.
    Millrud CR; Bergenfelz C; Leandersson K
    Oncotarget; 2017 Jan; 8(2):3649-3665. PubMed ID: 27690299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression.
    Cheng JN; Yuan YX; Zhu B; Jia Q
    Front Cell Dev Biol; 2021; 9():740827. PubMed ID: 35004667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.